Jiangsu Apon Medical Technology Co Ltd Class A Net Asset Quality Index
Jiangsu Apon Medical Technology Co Ltd Class A net asset quality index. Jiangsu Apon Medical Technology Co Ltd Class A (300753) has a Net Asset Quality Index of 81.7% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥839.64 Million minus total liabilities of CN¥153.56 Million yields net assets of CN¥686.08 Million. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Jiangsu Apon Medical Technology Co Ltd C for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Jiangsu Apon Medical Technology Co Ltd Class A (2014–2024)
Net asset quality index of Jiangsu Apon Medical Technology Co Ltd Class A from 2014 to 2024. This chart shows how Jiangsu Apon Medical Technology Co Ltd Class A's Net Asset Quality Index has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the index stands at 81.7%, representing net assets of CN¥686.08 Million against total assets of CN¥839.64 Million CNY. Check Jiangsu Apon Medical Technology Co Ltd C strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Jiangsu Apon Medical Technology Co Ltd Class A Net Asset Quality Index by Year (2014–2024)
Jiangsu Apon Medical Technology Co Ltd Class A net asset quality index by year from 2014 to 2024. The table below presents the year-by-year Net Asset Quality Index for Jiangsu Apon Medical Technology Co Ltd Class A from 2014 to 2024, covering 11 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Jiangsu Apon Medical Technology Co Ltd C stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 82.0% | CN¥707.86 Million | CN¥863.49 Million | CN¥155.62 Million | ▲ +0.9 pp |
| 2023 | 81.1% | CN¥697.20 Million | CN¥859.57 Million | CN¥162.38 Million | ▲ +2.2 pp |
| 2022 | 78.9% | CN¥686.36 Million | CN¥870.21 Million | CN¥183.85 Million | ▼ -7.9 pp |
| 2021 | 86.8% | CN¥780.52 Million | CN¥899.06 Million | CN¥118.54 Million | ▼ -2.6 pp |
| 2020 | 89.4% | CN¥739.84 Million | CN¥827.24 Million | CN¥87.40 Million | ▲ +0.4 pp |
| 2019 | 89.1% | CN¥674.88 Million | CN¥757.64 Million | CN¥82.76 Million | ▼ -0.1 pp |
| 2018 | 89.2% | CN¥613.39 Million | CN¥687.96 Million | CN¥74.56 Million | ▲ +5.3 pp |
| 2017 | 83.8% | CN¥279.38 Million | CN¥333.26 Million | CN¥53.87 Million | ▲ +5.9 pp |
| 2016 | 78.0% | CN¥229.59 Million | CN¥294.51 Million | CN¥64.92 Million | ▼ -2.7 pp |
| 2015 | 80.7% | CN¥145.40 Million | CN¥180.28 Million | CN¥34.88 Million | ▲ +10.4 pp |
| 2014 | 70.3% | CN¥81.37 Million | CN¥115.80 Million | CN¥34.43 Million | — |